ReviewClinical microbiology reviews2005
Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.
Review in Clinical microbiology reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 241 citations in OpenAlex.
- A systematic review and meta-analysis of the epidemiology of pathogenic Escherichia coli of calves and the role of calves as reservoirs for human pathogenic E. coli.Frontiers in cellular and infection microbiology · 2015Pooled it
- Biophysical and functional characterization of the Escherichia coli Dr fimbrial envelope reveals its importance for pathogenesis and lithogenesis.PLoS pathogens · 2026Article
- Diversity and Antimicrobial Resistance Profiles of ESBL-ProducingPathogens (Basel, Switzerland) · 2026Article
- Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026Review
- Molecular characterization of extended-spectrum β-lactamase (ESBL) and virulent genes in multidrug-resistant Escherichia coli isolated from pharmaceutical and environmental Wastewaters in Dhaka, Bangladesh.Scientific reports · 2026Article
- Comparative genomic and phenotypic analysis of Escherichia coli ST1193 and ST131 from urinary and bloodstream infections: insights into resistance, virulence, and divergent strategies.BMC infectious diseases · 2025Article
- Sexually transmitted enteric infections in men who have sex with men.Clinical microbiology reviews · 2025Review
- Virulence profiles and antibiotic resistance patterns ofOpen veterinary journal · 2025Article
- Emerging hybrid shigatoxigenic and enteropathogenicClinical microbiology reviews · 2025Review
- Virulence and Antibiotic Resistance of aEPEC/STECPathogens (Basel, Switzerland) · 2025Article
- Revisiting Pathogen Exploitation of Clathrin-Independent Endocytosis: Mechanisms and Implications.Cells · 2025Review
- Structural basis of aggregative adherence fimbriae II interactions with sialic acid, mucin, and human intestinal cells.Infection and immunity · 2025Article
- Identification and Evaluation of Pathogenic Genes (Reports of biochemistry & molecular biology · 2023Article
- UropathogenicMicroorganisms · 2023Review
- The Diversity ofMicroorganisms · 2023Review
- Role of gut microbiota in infectious and inflammatory diseases.Frontiers in microbiology · 2023Review
- Interactions of pathogenicFrontiers in immunology · 2023Review
- Differential Afa/Dr Fimbriae Expression in the Multidrug-Resistant Escherichia coli ST131 Clone.mBio · 2022Article
- Phylogrouping and characterization ofFrontiers in medicine · 2022Article
- Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last few years, dramatic increases in our knowledge about diffusely adhering Escherichia coli (DAEC) pathogenesis have taken place. The typical class of DAEC includes E. coli strains harboring AfaE-I, AfaE-II, AfaE-III, AfaE-V, Dr, Dr-II, F1845, and NFA-I adhesins (Afa/Dr DAEC); these strains (i) have an identical genetic organization and (ii) allow binding to human decay-accelerating factor (DAF) (Afa/Dr(DAF) subclass) or carcinoembryonic antigen (CEA) (Afa/Dr(CEA) subclass). The atypical class of DAEC includes two subclasses of strains; the atypical subclass 1 includes E. coli strains that express AfaE-VII, AfaE-VIII, AAF-I, AAF-II, and AAF-III adhesins, which (i) have an identical genetic organization and (ii) do not bind to human DAF, and the atypical subclass 2 includes E. coli strains that harbor Afa/Dr adhesins or others adhesins promoting diffuse adhesion, together with pathogenicity islands such as the LEE pathogenicity island (DA-EPEC). In this review, the focus is on Afa/Dr DAEC strains that have been found to be associated with urinary tract infections and with enteric infection. The review aims to provide a broad overview and update of the virulence aspects of these intriguing pathogens. Epidemiological studies, diagnostic techniques, characteristic molecular features of Afa/Dr operons, and the respective role of Afa/Dr adhesins and invasins in pathogenesis are described. Following the recognition of membrane-bound receptors, including type IV collagen, DAF, CEACAM1, CEA, and CEACAM6, by Afa/Dr adhesins, activation of signal transduction pathways leads to structural and functional injuries at brush border and junctional domains and to proinflammatory responses in polarized intestinal cells. In addition, uropathogenic Afa/Dr DAEC strains, following recognition of beta(1) integrin as a receptor, enter epithelial cells by a zipper-like, raft- and microtubule-dependent mechanism. Finally, the presence of other, unknown virulence factors and the way that an Afa/Dr DAEC strain emerges from the human intestinal microbiota as a "silent pathogen" are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.